One patient had ERBB2 mutation and might benefit from anti-HER2 therapies, including neratinib or pyrotinib.17,18 In addition, 49 patients (39.2%) had at least 1 alteration predicting response to a drug registered for tumor types other than breast cancer (Fig. 1b-c). Here, ERBB2 is linked to neoplasm.